Eye health company Bausch + Lomb has received CE mark approval for its LuxLife intraocular lens (IOL), enhancing its portfolio of vision solutions.
The preloaded LuxLife IOL provides patients with a natural, continuous vision from distance to near and cataract surgeons with diverse lens options.
Also, it advances cataract surgery options following the recent launch of enVista Envy lenses in the US and Canada and enVista Aspire IOLs in Europe.
The lens combines Pure Refractive Optics (PRO) Technology and two Allied Ray Technology (ART) Zones to optimise light focus without losing light to the retina.
It addresses a wide range of corneal astigmatism, with cylinders from +0.75D to +6.00D, enabling treatment for 79.5% of patients with more than 0.5D of astigmatism before surgery.
Surgeons benefit from the preloaded lens’ dual injector system, allowing for flexible implantation techniques.
The LuxLife IOL has shown excellent results in a multicenter clinical study, delivering superior binocular visual outcomes at all distances.
Patient satisfaction with the LuxLife lens is notably high, with 95.6% of patients reporting independence from spectacles at intermediate distances and 89.5% at near distances.
Bausch + Lomb plans to launch LuxLife lenses in Europe, with a toric version to follow.
Regulatory submissions for other countries are in progress, expanding the reach of the advanced lens technology.
Bausch + Lomb surgical president Luc Bonnefoy said: “This platform has delivered both quality of vision and patient satisfaction since its introduction.
“LuxLife is an example of how we plan to build on that success by developing premium options designed to meet the evolving needs of surgeons and patients.”
Multicenter clinical study investigator Francisco Javier Castro Alonso said: “The LuxLife lens provides truly multifocal optical performance, offering an extensive range of clear vision from distance to near. I consider this lens a first-choice option for patients seeking freedom from glasses at all distances.”
Recently, Bausch + Lomb identified the event that led to its recent voluntary recall of intraocular lenses (IOLs) on the enVista platform and will return these models to market.
